11611 N. MERIDIAN ST, CARMEL, IN
Annual Report to Security Holders
At The Market Offering Agreement with Craig-Hallum Capital Group
Neuraxis, Inc. Reports Preliminary Q1 2026 Financial Results
FDA 510(k) Clearance for NeurAxis' PENFS Technology for FAP Treatment
Neuraxis, Inc. Reports Q3 2025 Financial Results and Cash Position
News, Underwriting Agreement, Legal Opinion
News, Material Contracts
Shareholder votes
Q1
FY 2025
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload